Search

Author/Creator Burris, Howard A

1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Issue 10031 (7th May 2016)

Authors:
Rosenberg, Jonathan E; Hoffman-Censits, Jean; Powles, Tom; van der Heijden, Michiel S; Balar, Arjun V; Necchi, Andrea; Dawson, Nancy; O'Donnell, Peter H; Balmanoukian, Ani; Loriot, Yohann; Srinivas, Sandy; Retz, Margitta M; Grivas, Petros; Joseph, Richard W; Galsky, Matthew D; Fleming, Mark T; Pe...
Journal:
Lancet
Issue:
Volume 387:Issue 10031(2016)
Page Start:
1909
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Issue 7 (July 2015)

Authors:
Hurvitz, Sara A; Andre, Fabrice; Jiang, Zefei; Shao, Zhimin; Mano, Max S; Neciosup, Silvia P; Tseng, Ling-Min; Zhang, Qingyuan; Shen, Kunwei; Liu, Donggeng; Dreosti, Lydia M; Burris, Howard A; Toi, Masakazu; Buyse, Marc E; Cabaribere, David; Lindsay, Mary-Ann; Rao, Shantha; Pacaud, Lida Bubuteish...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 7(2015:Jul.)
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings. (19th February 2022)

Authors:
Sturgill, Emma G; Misch, Amanda; Jones, Carissa C; Luckett, Daniel; Fu, Xiaotong; Schlauch, Dan; Jones, Suzanne F; Burris, Howard A; Spigel, David R; McKenzie, Andrew J
Journal:
Oncologist
Issue:
Volume 27:Number 3(2022)
Page Start:
175
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Issue 1 (January 2017)

Authors:
Rudin, Charles M; Pietanza, M Catherine; Bauer, Todd M; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S; Byers, Lauren A; Johnson, Melissa L; Burris, Howard A; Robert, Francisco; Han, Tae H; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, ...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 1(2017:Jan.)
Page Start:
42
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Issue 9 (September 2015)

Authors:
Reid, Tony; Oronsky, Bryan; Scicinski, Jan; Scribner, Curt L; Knox, Susan J; Ning, Shoucheng; Peehl, Donna M; Korn, Ron; Stirn, Meaghan; Carter, Corey A; Oronsky, Arnold; Taylor, Michael J; Fitch, William L; Cabrales, Pedro; Kim, Michelle M; Burris, Howard A; Lao, Christopher D; Abrouk, Nacer E D...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Issue 9 (September 2015)

Authors:
Reid, Tony; Oronsky, Bryan; Scicinski, Jan; Scribner, Curt L; Knox, Susan J; Ning, Shoucheng; Peehl, Donna M; Korn, Ron; Stirn, Meaghan; Carter, Corey A; Oronsky, Arnold; Taylor, Michael J; Fitch, William L; Cabrales, Pedro; Kim, Michelle M; Burris, Howard A; Lao, Christopher D; Abrouk, Nacer E D...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Issue 4 (April 2018)

Authors:
Burris, Howard A; Flinn, Ian W; Patel, Manish R; Fenske, Timothy S; Deng, Changchun; Brander, Danielle M; Gutierrez, Martin; Essell, James H; Kuhn, John G; Miskin, Hari P; Sportelli, Peter; Weiss, Michael S; Vakkalanka, Swaroop; Savona, Michael R; O'Connor, Owen A
Journal:
Lancet oncology
Issue:
Volume 19:Issue 4(2018)
Page Start:
486
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗